A new publication involving icatibant was announced on October 30, 2026. The article, titled "Advances in pharmacotherapy for children aged 2 to <12 years with hereditary angioedema: what is the current state of play?", appeared in the journal Expert Opinion on Pharmacotherapy.
The publication is listed under PubMed ID 42948982. No specific findings, results, or conclusions were included in the event data provided. The title indicates the publication addresses pharmacotherapy approaches, including icatibant, for pediatric patients aged 2 to under 12 years who have hereditary angioedema.
Icatibant remains an approved compound according to current regulatory status. This brief reports only the existence and basic details of the publication as recorded, including its title, journal, and publication date. No efficacy, safety, or outcome data from the publication's content are described here, as such details were not part of the provided event information.
Readers interested in additional context about icatibant, including its approved uses and background, can consult the compound overview for further information.